Literature DB >> 11381060

Inhibitory effects of antithrombin III against leukocyte rolling and infiltration during endotoxin-induced uveitis in rats.

K Yamashiro1, J Kiryu, A Tsujikawa, M Honjo, A Nonaka, K Miyamoto, Y Honda, H Tanihara, Y Ogura.   

Abstract

PURPOSE: This study was designed to investigate the suppressive effects of antithrombin (AT)III on inflammatory reactions during endotoxin-induced uveitis (EIU) in rats by studying leukocyte-endothelium interactions.
METHODS: EIU was induced in Lewis rats by footpad injection of lipopolysaccharide (LPS). ATIII was administered immediately after or at 6 hours after LPS injection. Its suppressive effects on inflammatory leukocyte behavior were evaluated in vivo with acridine orange digital fluorography. Clinical signs of inflammation were also examined, and aqueous humor (AH) was collected to evaluate leukocyte infiltration and protein leakage. In a separate experiment, P-selectin mRNA expression was studied in the iris-ciliary body (ICB) and the retina.
RESULTS: After treatment with ATIII, leukocyte rolling was substantially inhibited along the retinal veins, suppressing subsequent leukocyte infiltration into the vitreous cavity. Similarly, leukocyte infiltration and protein leakage into the AH were significantly reduced with ATIII treatment. The clinical grade of EIU was substantially lower in ATIII-treated rats. In addition, delayed administration of ATIII after EIU induction significantly attenuated these inflammatory reactions. The levels of P-selectin mRNA expression in both ICB and retina, which were upregulated after LPS injection, were substantially lower in the ATIII-treated rats.
CONCLUSIONS: ATIII treatment significantly inhibited inflammatory reactions induced with LPS. Its suppressive effects on P-selectin expression could contribute to the attenuation of leukocyte infiltration, possibly by inhibiting leukocyte rolling. The current findings suggest that ATIII may have a role in the management of patients with uveitis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11381060

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  9 in total

1.  HS3ST1 genotype regulates antithrombin's inflammomodulatory tone and associates with atherosclerosis.

Authors:  Nicole C Smits; Takashi Kobayashi; Pratyaksh K Srivastava; Sladjana Skopelja; Julianne A Ivy; Dustin J Elwood; Radu V Stan; Gregory J Tsongalis; Frank W Sellke; Peter L Gross; Michael D Cole; James T DeVries; Aaron V Kaplan; John F Robb; Scott M Williams; Nicholas W Shworak
Journal:  Matrix Biol       Date:  2017-01-23       Impact factor: 11.583

2.  In vivo evaluation of ocular inflammatory responses in experimental diabetes.

Authors:  H Tamura; J Kiryu; K Miyamoto; K Nishijima; H Katsuta; S Miyahara; F Hirose; Y Honda; N Yoshimura
Journal:  Br J Ophthalmol       Date:  2005-08       Impact factor: 4.638

3.  Vascular adhesion protein-1 blockade suppresses choroidal neovascularization.

Authors:  Kousuke Noda; Haicheng She; Toru Nakazawa; Toshio Hisatomi; Shintaro Nakao; Lama Almulki; Souska Zandi; Shinsuke Miyahara; Yasuhiro Ito; Kennard L Thomas; Rebecca C Garland; Joan W Miller; Evangelos S Gragoudas; Yukihiko Mashima; Ali Hafezi-Moghadam
Journal:  FASEB J       Date:  2008-04-24       Impact factor: 5.191

4.  The anti-inflammatory action of Bothrops jararaca snake antithrombin on acute inflammation induced by carrageenan in mice.

Authors:  Karen de Morais-Zani; Fernanda Peixoto Barbosa Nunes; Jacilene Barbosa da Silva; Márcio José Ferreira; Kathleen Fernandes Grego; Mônica Lopes-Ferreira; Aparecida Sadae Tanaka; Anita Mitico Tanaka-Azevedo
Journal:  Inflamm Res       Date:  2013-05-12       Impact factor: 4.575

5.  The effects of sepsis on endothelium and clinical implications.

Authors:  Elena V Dolmatova; Keke Wang; Rohan Mandavilli; Kathy K Griendling
Journal:  Cardiovasc Res       Date:  2021-01-01       Impact factor: 10.787

6.  Antithrombin significantly influences platelet adhesion onto immobilized fibrinogen in an in-vitro system simulating low flow.

Authors:  Robert Loncar; Uwe Kalina; Volker Stoldt; Volker Thomas; Rüdiger E Scharf; Aleksandar Vodovnik
Journal:  Thromb J       Date:  2006-10-13

7.  Antithrombin III Protects Against Contrast-Induced Nephropathy.

Authors:  Zeyuan Lu; Dongsheng Cheng; Jianyong Yin; Rui Wu; Guangyuan Zhang; Qing Zhao; Niansong Wang; Feng Wang; Mingyu Liang
Journal:  EBioMedicine       Date:  2017-02-12       Impact factor: 8.143

8.  The relationship between antithrombin administration and inflammation during veno-venous ECMO.

Authors:  Mauro Panigada; Elena Spinelli; Stefano De Falco; Dario Consonni; Cristina Novembrino; Massimo Boscolo Anzoletti; Giovanna Panarello; Giovanna Occhipinti; Claudia C Dos Santos; Antonio Pesenti; Antonio Arcadipane; Giacomo Grasselli
Journal:  Sci Rep       Date:  2022-08-22       Impact factor: 4.996

9.  Antithrombin III prevents progression of chronic kidney disease following experimental ischaemic-reperfusion injury.

Authors:  Jianyong Yin; Feng Wang; Yiwei Kong; Rui Wu; Guangyuan Zhang; Niansong Wang; Ling Wang; Zeyuan Lu; Mingyu Liang
Journal:  J Cell Mol Med       Date:  2017-08-02       Impact factor: 5.310

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.